TY - JOUR
T1 - Excessive proteostasis contributes to pathology in Fragile X Syndrome
AU - Ribeiro dos Louros, Susana
AU - Seo, Sang
AU - Maio, Beatriz
AU - Martinez Gonzalez, Cristina
AU - Gonzalez-Lozano, Miguel A
AU - Muscas, Melania
AU - Verity, Nicholas
AU - Wills, Jimi
AU - Li, Ka Wan
AU - Nolan, Matthew F
AU - Osterweil, Emily
PY - 2022/12/9
Y1 - 2022/12/9
N2 - In fragile X syndrome (FX), the leading monogenic cause of autism, excessive neuronal protein synthesis is a core pathophysiology; however, an overall increase in protein expression is not observed. Here, we tested whether excessive protein synthesis drives a compensatory rise in protein degradation that is protective for FX mouse model (Fmr1−/y) neurons. Surprisingly, although we find a significant increase in protein degradation through ubiquitin proteasome system (UPS), this contributes to pathological changes. Normalizing proteasome activity with bortezomib corrects excessive hippocampal protein synthesis and hyperactivation of neurons in the inferior colliculus (IC) in response to auditory stimulation. Moreover, systemic administration of bortezomib significantly reduces the incidence and severity of audiogenic seizures (AGS) in the Fmr1−/y mouse, as does genetic reduction of proteasome, specifically in the IC. Together, these results identify excessive activation of the UPS pathway in Fmr1−/y neurons as a contributor to multiple phenotypes that can be targeted for therapeutic intervention.
AB - In fragile X syndrome (FX), the leading monogenic cause of autism, excessive neuronal protein synthesis is a core pathophysiology; however, an overall increase in protein expression is not observed. Here, we tested whether excessive protein synthesis drives a compensatory rise in protein degradation that is protective for FX mouse model (Fmr1−/y) neurons. Surprisingly, although we find a significant increase in protein degradation through ubiquitin proteasome system (UPS), this contributes to pathological changes. Normalizing proteasome activity with bortezomib corrects excessive hippocampal protein synthesis and hyperactivation of neurons in the inferior colliculus (IC) in response to auditory stimulation. Moreover, systemic administration of bortezomib significantly reduces the incidence and severity of audiogenic seizures (AGS) in the Fmr1−/y mouse, as does genetic reduction of proteasome, specifically in the IC. Together, these results identify excessive activation of the UPS pathway in Fmr1−/y neurons as a contributor to multiple phenotypes that can be targeted for therapeutic intervention.
U2 - 10.1016/j.neuron.2022.11.012
DO - 10.1016/j.neuron.2022.11.012
M3 - Article
SN - 0896-6273
JO - Neuron
JF - Neuron
ER -